-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Cryo-Cell International (OTCMKTS:CCEL) Share Price Crosses Below Two Hundred Day Moving Average of $5.87
Cryo-Cell International (OTCMKTS:CCEL) Share Price Crosses Below Two Hundred Day Moving Average of $5.87
Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating)'s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.87 and traded as low as $4.75. Cryo-Cell International shares last traded at $4.84, with a volume of 1,067 shares changing hands.
Analyst Ratings Changes
Separately, Maxim Group assumed coverage on Cryo-Cell International in a report on Monday, August 29th. They set a "buy" rating and a $12.00 target price for the company.
Get Cryo-Cell International alerts:Cryo-Cell International Price Performance
The company has a market capitalization of $41.24 million, a price-to-earnings ratio of 32.27 and a beta of 0.35. The stock has a 50 day simple moving average of $5.46 and a two-hundred day simple moving average of $5.87.
Cryo-Cell International (OTCMKTS:CCEL – Get Rating) last posted its earnings results on Friday, October 14th. The company reported $0.06 EPS for the quarter. Cryo-Cell International had a return on equity of 49.62% and a net margin of 4.34%. The business had revenue of $7.70 million for the quarter.Insider Transactions at Cryo-Cell International
In related news, CEO David Portnoy purchased 10,000 shares of the stock in a transaction that occurred on Monday, November 14th. The shares were purchased at an average price of $4.80 per share, with a total value of $48,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 220,080 shares in the company, valued at approximately $1,056,384. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last 90 days, insiders have bought 34,366 shares of company stock worth $167,193. Corporate insiders own 33.80% of the company's stock.
Hedge Funds Weigh In On Cryo-Cell International
A hedge fund recently raised its stake in Cryo-Cell International stock. Massmutual Trust Co. FSB ADV raised its holdings in Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating) by 63.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 124,135 shares of the company's stock after purchasing an additional 48,100 shares during the quarter. Massmutual Trust Co. FSB ADV owned 1.47% of Cryo-Cell International worth $732,000 as of its most recent filing with the Securities and Exchange Commission. 9.01% of the stock is currently owned by institutional investors and hedge funds.
About Cryo-Cell International
(Get Rating)
Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases.
Featured Stories
- Get a free copy of the StockNews.com research report on Cryo-Cell International (CCEL)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.
Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating)'s share price crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $5.87 and traded as low as $4.75. Cryo-Cell International shares last traded at $4.84, with a volume of 1,067 shares changing hands.
在周二的交易中，Cryo-Cell International，Inc.的股价跌破了200日移动均线。该股的200日移动均线为5.87美元，最低交易价格为4.75美元。Cryo-Cell International的股票最新报4.84美元，成交量为1,067股。
Analyst Ratings Changes
分析师评级发生变化
Separately, Maxim Group assumed coverage on Cryo-Cell International in a report on Monday, August 29th. They set a "buy" rating and a $12.00 target price for the company.
另外，Maxim Group在8月29日星期一的一份报告中对冷冻细胞国际进行了报道。他们为该公司设定了“买入”评级和12.00美元的目标价。
Cryo-Cell International Price Performance
低温电池国际性价比
The company has a market capitalization of $41.24 million, a price-to-earnings ratio of 32.27 and a beta of 0.35. The stock has a 50 day simple moving average of $5.46 and a two-hundred day simple moving average of $5.87.
该公司市值为4,124万美元，市盈率为32.27倍，贝塔系数为0.35。该股的50日简单移动均线切入位为5.46美元，200日简单移动均线切入位为5.87美元。
Insider Transactions at Cryo-Cell International
Cryo-Cell International的内幕交易
In related news, CEO David Portnoy purchased 10,000 shares of the stock in a transaction that occurred on Monday, November 14th. The shares were purchased at an average price of $4.80 per share, with a total value of $48,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 220,080 shares in the company, valued at approximately $1,056,384. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last 90 days, insiders have bought 34,366 shares of company stock worth $167,193. Corporate insiders own 33.80% of the company's stock.
在相关新闻中，首席执行官David·波特诺伊在11月14日星期一的一笔交易中购买了10,000股该股。这些股票是以每股4.80美元的平均价格购买的，总价值为48,000.00美元。收购完成后，首席执行官现在直接拥有公司220,080股，价值约1,056,384美元。这笔交易是在提交给美国证券交易委员会的一份法律文件中披露的，该文件可在此超链接。在过去的90天里，内部人士购买了34,366股公司股票，价值167,193美元。公司内部人士持有该公司33.80%的股份。
Hedge Funds Weigh In On Cryo-Cell International
对冲基金看好Cryo-Cell International
A hedge fund recently raised its stake in Cryo-Cell International stock. Massmutual Trust Co. FSB ADV raised its holdings in Cryo-Cell International, Inc. (OTCMKTS:CCEL – Get Rating) by 63.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 124,135 shares of the company's stock after purchasing an additional 48,100 shares during the quarter. Massmutual Trust Co. FSB ADV owned 1.47% of Cryo-Cell International worth $732,000 as of its most recent filing with the Securities and Exchange Commission. 9.01% of the stock is currently owned by institutional investors and hedge funds.
一家对冲基金最近增持了Cryo-Cell International股票。根据最近提交给美国证券交易委员会的文件，MassMutual Trust Co.FSB ADV在第二季度将其在Cryo-Cell International，Inc.(场外交易市场代码：CCEL-GET Rating)的持股增加了63.3%。该机构投资者在本季度额外购买了48,100股后，持有该公司124,135股股票。截至最近提交给美国证券交易委员会(Securities And Exchange Commission)的文件，MassMutual Trust Co.FSB ADV持有Cryo-Cell International 1.47%的股份，价值73.2万美元。该公司9.01%的股票目前由机构投资者和对冲基金持有。
About Cryo-Cell International
关于冷冻细胞国际公司
(Get Rating)
(获取评级)
Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases.
国际冷冻细胞公司从事细胞处理和低温细胞存储，专注于收集和保存供家庭使用的脐带血干细胞。它提供脐带组织服务，存储部分脐带组织，脐带组织是间充质干细胞的来源，用于再生医学，用于治疗一系列疾病，包括心脏、肾脏疾病、肌萎缩侧索硬化症、伤口愈合和自身免疫性疾病。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Cryo-Cell International (CCEL)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
- 免费获取StockNews.com关于低温细胞国际(CCEL)的研究报告
- Salesforce裁员，尽管面临挑战，但收入强劲
- 三只CBD股票将主宰一个萌芽行业
- 60/40的投资组合组合还在《时尚》杂志上流行吗？
- 机构对ADI的支持仍然很高
- 微软股票：是时候备份卡车了吗？
Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.
接受《冷冻细胞国际日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Cryo-Cell International和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧